CAJ | 학술논문

目的：探讨氟维司群(FUL)对受体阳性转移性乳腺癌(MBC)患者的疗效及安全性。方法24例患者接受氟维司群治疗,0、14及28 d各肌内注射250 mg,随后每28天肌内注射250 mg,直至肿瘤进展。主要研究终点为至疾病进展时间(TTP),次要终点为客观有效率(ORR)及临床获益率(CBR)。结果本组24例患者中位TTP为4.4个月,ORR为8.3%(2/24), CBR为25.0%,其中部分缓解(PR)2例,疾病稳定(SD)超过24周4例。氟维司群的疗效与患者术后无病生存期(DFS)及解救治疗线数等因素相关。全组不良反应较轻微。结论氟维司群是治疗MBC患者的有效内分泌治疗药物,安全性较好。
목적：탐토불유사군(FUL)대수체양성전이성유선암(MBC)환자적료효급안전성。방법24례환자접수불유사군치료,0、14급28 d각기내주사250 mg,수후매28천기내주사250 mg,직지종류진전。주요연구종점위지질병진전시간(TTP),차요종점위객관유효솔(ORR)급림상획익솔(CBR)。결과본조24례환자중위TTP위4.4개월,ORR위8.3%(2/24), CBR위25.0%,기중부분완해(PR)2례,질병은정(SD)초과24주4례。불유사군적료효여환자술후무병생존기(DFS)급해구치료선수등인소상관。전조불량반응교경미。결론불유사군시치료MBC환자적유효내분비치료약물,안전성교호。
Objective To evaluate the effect and safety of fulvestrant in the treatment of patients with receptor-positive metastatic breast cancer(MBC).Methods Selected 24 patients as research objects. All for fulvestrant: 250 mg/d on 0, 14th, 28th day, and 250 mg every 28 days thereafter. The primary endpoint was to find the time to progression(TTP), secondary endpoints included objective response rate(ORR) and clinical benefit rate (CBR).Results The median TTP was 4.4 months with an overall response rate of 8.3%, CBR was 25%, including 2 patients who showed a partial response(PR) and 4 patients who achieved stable disease(SD)≥24 weeks. Efficacy of fulvestrant had associated with disease free survival(DFS) and advanced treatment lines. The treatment was well tolerated.Conclusion Fulvestrant is effective and tolerable in the treatment of patients with MBC.